K. Neben

发表

Carcinoma of Unknown Primary – an Orphan Disease?

A. Schneeweiss, A. Krämer, G. Folprecht, 2008, Breast Care.

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

Thomas W. Mühleisen, T. Mühleisen, M. Nöthen, 2011, Nature Genetics.

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

Thomas W. Mühleisen, T. Mühleisen, M. Nöthen, 2013, Nature Genetics.

Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Tobias Bäuerle, Stefan Delorme, Hans-Ulrich Kauczor, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

T Hielscher, B Wagner, D. Hose, 2014, Leukemia.

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

D. Hose, H. Goldschmidt, A. Jauch, 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile.

A. Krämer, A. Ho, K. Neben, 2003, Blood.

Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance

T Hielscher, H. Goldschmidt, S. Delorme, 2014, Leukemia.

Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.

H. Kauczor, H. Goldschmidt, S. Delorme, 2014, European journal of radiology.

Current status and developments in diagnosis and therapy of multiple myeloma

H. Goldschmidt, K. Neben, J. Hillengass, 2009, Journal of Cancer Research and Clinical Oncology.

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

A. Krämer, A. Ho, A. Benner, 2011 .

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

T. Rème, J. Rossi, B. Klein, 2013, Blood.

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2013, Experimental hematology.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study

H. Goldschmidt, U. Sommer, G. Schmidmaier, 2012, Journal of surgical oncology.

Impaired thymopoietic potential of immature CD3(-)CD4(+)CD8(-) T cell precursors from SIV-infected rhesus monkeys.

H. Petry, T. Hünig, K. Neben, 1999, International immunology.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

H. Goldschmidt, A. Ho, M. Zeier, 2014, Bone Marrow Transplantation.

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

A. Ho, A. Benner, P. Dreger, 2008, Annals of Hematology.

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

H. Goldschmidt, A. Ho, T. Moehler, 2002, Blood.

Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.

H. Goldschmidt, A. Ho, T. Bruckner, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

cytogenetic risk profile Centrosome aberrations in acute myeloid leukemia are correlated with

A. Krämer, A. Ho, K. Neben, 2013 .

Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial

H. Goldschmidt, Y. Ko, A. Ho, 2016, British journal of haematology.

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma

T. Hielscher, A. Krämer, A. Ho, 2012, American journal of hematology.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Axel Benner, John D. Shaughnessy, Thomas Hielscher, 2011, Haematologica.

Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine

Thomas Hielscher, Hartmut Goldschmidt, Dirk Hose, 2011, Clinical Cancer Research.

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.

J. Ficker, A. Schueler, W. Brueckl, 2022, Journal of geriatric oncology.

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy

A. Ho, S. Dietrich, K. Neben, 2010, Leukemia & lymphoma.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

H. Goldschmidt, A. Ho, U. Hegenbart, 2008, Annals of Hematology.

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.

D. Hose, H. Goldschmidt, A. Ho, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma

H. Goldschmidt, E. Buss, A. Ho, 2015, Transfusion.

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

H. Goldschmidt, S. Hohaus, A. Ho, 2000, Annals of Hematology.

Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression

A. Schneeweiss, G. Bastert, A. Krämer, 2003, International journal of cancer.

Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.

D. Hose, H. Goldschmidt, T. Hielscher, 2012 .

Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.

Axel Benner, Stefan Joos, Andrey Korshunov, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REVIEW Centrosome replication, genomic instability and cancer

A. Ho, K. Neben, 2002 .

Centrosome replication, genomic instability and cancer

A. Krämer, A. Ho, K. Neben, 2002, Leukemia.

Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma

H. Goldschmidt, A. Jauch, A. Ho, 2013, European journal of haematology.

Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma

H. Müller-Hermelink, G. Ott, A. Krämer, 2003, Leukemia.

Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.

F. Kokocinski, P. Lichter, A. Korshunov, 2004, Cancer research.

Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q

G. Reifenberger, P. Lichter, C. Hartmann, 2007, Oncogene.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2010, Haematologica.

Survival for Medulloblastoma Revealed STK15 as Independent Predictor Microarray-Based Screening for Molecular Markers in

A. Korshunov, A. Benner, K. Neben, 2013 .

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

J. Hasford, T. Brümmendorf, D. Hossfeld, 2016, Leukemia.

Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age.

P. Lichter, A. Korshunov, A. Benner, 2003, The American journal of pathology.

Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma.

T. Hielscher, A. Krämer, K. Neben, 2014, Deutsches Arzteblatt international.

Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab‐CHOP immunochemotherapy with and without consolidating radiotherapy

K. Herfarth, T. Hielscher, A. Ho, 2010, European journal of haematology.

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

H. Goldschmidt, A. Ho, A. Benner, 2001, British journal of haematology.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood Cancer Journal.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood cancer journal.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

H. Goldschmidt, A. Ho, A. Benner, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Asta Försti, Lewin Eisele, Hartmut Goldschmidt, 2013, Nature Genetics.

Targeting the BRAF V600E mutation in multiple myeloma.

H. Goldschmidt, P. Schirmacher, R. Penzel, 2013, Cancer discovery.

Sorafenib in patients with refractory or recurrent multiple myeloma

D. Hose, H. Goldschmidt, I. Schmidt-Wolf, 2013, Hematological oncology.

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

H. Goldschmidt, M. Hundemer, T. Bruckner, 2014, Journal of clinical apheresis.

Molecular Characterization of a Respiratory Syncytial Virus Outbreak in a Hematology Unit in Heidelberg, Germany

U. Buchholz, A. Ho, P. Dreger, 2012, Journal of Clinical Microbiology.

Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes

F. Kokocinski, P. Lichter, A. Krämer, 2004, Oncogene.

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

H. Goldschmidt, T. Hielscher, A. Ho, 2011, Annals of Hematology.

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.

H. Goldschmidt, A. Ho, A. Benner, 2001, Blood.

Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype

F. Kokocinski, R. Eils, W. Hiddemann, 2005, Oncogene.

Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling

G. Reifenberger, P. Lichter, A. von Deimling, 2006, International journal of cancer.

Microarray‐based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression

F. Kokocinski, G. Reifenberger, P. Lichter, 2005, International journal of cancer.

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

A. Krämer, A. Ho, A. Benner, 2015, British journal of haematology.

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

P. Sonneveld, H. Johnsen, M. Nyegaard, 2012, Haematologica.

High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B‐cell chronic lymphocytic leukemia

A. Jauch, A. Krämer, A. Ho, 2007, International journal of cancer.

Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome.

D. Jäger, A. Krämer, G. Folprecht, 2008, Deutsches Arzteblatt international.

Angiogenesis in hematologic malignancies.

H. Goldschmidt, A. Ho, T. Moehler, 2003, Annals of hematology.

Angiogenesis in hematologic malignancies

H. Goldschmidt, A. Ho, T. Moehler, 2001, Annals of Hematology.

Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.

H. Goldschmidt, A. Ho, G. Mikus, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

molecule-6 cells through carcinoembryonic antigen-related cell adhesion Tumor cells in multiple myeloma patients inhibit myeloma-reactive

T. Rème, J. Rossi, B. Klein, 2013 .

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide

H. Goldschmidt, A. Ho, T. Moehler, 2004, Annals of Hematology.

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

D. Hose, H. Goldschmidt, A. Jauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

chemotherapy Salvage therapy for multiple myeloma with thalidomide and CED

A. Ho, A. Benner, T. Moehler, 2013 .

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

D. Hose, H. Goldschmidt, A. Jauch, 2011, Blood.

Autologous retransplantation for patients with recurrent multiple myeloma

D. Hose, H. Goldschmidt, A. Ho, 2013, Cancer.

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

D. Hose, H. Goldschmidt, S. Delorme, 2012, Haematologica.

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

D. Hose, H. Goldschmidt, A. Jauch, 2011, Cancer.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Axel Benner, Thomas Hielscher, Bart Barlogie, 2008, Blood.

Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems.

H. Kauczor, H. Goldschmidt, S. Delorme, 2010, Radiology.

Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

H. Kauczor, H. Goldschmidt, S. Delorme, 2009, Radiology.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

T. Rème, B. Klein, J. Moreaux, 2011, Srpski arhiv za celokupno lekarstvo.

Longitudinal whole body MRI (wbMRI) in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.

H. Goldschmidt, A. Ho, M. Merz, 2013 .

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

H. Goldschmidt, A. Palumbo, P. Sonneveld, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Centrosome aberrations in hematological malignancies

A. Krämer, A. Ho, K. Neben, 2005, Cell biology international.

Extended resection of a plasmocytoma of bone and an amyloidoma of the chest wall.

H. Dienemann, P. Schnabel, U. Hegenbart, 2013, The Annals of thoracic surgery.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation

H. Kauczor, D. Hose, H. Goldschmidt, 2009, Clinical Cancer Research.

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

K. Herfarth, T. Hielscher, M. Hensel, 2009 .

Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study.

A. Krämer, A. Ho, A. Benner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin’s-lymphoma: First interim results of a prospective randomised phase II study

A. Krämer, A. Ho, A. Benner, 2005 .

Changes in Severity of Influenza A(H1N1)pdm09 Infection from Pandemic to First Postpandemic Season, Germany

P. Schnitzler, C. Eisenbach, S. Geis, 2013, Emerging infectious diseases.

Bone marrow microcirculation analysis in multiple myeloma by contrast‐enhanced dynamic magnetic resonance imaging

G. van Kaick, H. Goldschmidt, A. Ho, 2001, International journal of cancer.

Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom

G. van Kaick, H. Goldschmidt, A. Ho, 2000, Der Radiologe.

Expression of centrosome‐associated gene products is linked to tetraploidization in mantle cell lymphoma

A. Rosenwald, G. Ott, P. Lichter, 2007, International journal of cancer.

High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.

H. Goldschmidt, A. Ho, A. Benner, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

First Results of a Phase-II Study with the New CXCR4 Antagonist POL6326 to Mobilize Hematopoietic Stem Cells (HSC) In Multiple Myeloma (MM)

H. Goldschmidt, A. Ho, K. Neben, 2010 .

Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology

H. Goldschmidt, B. Stieltjes, F. Laun, 2011, British journal of haematology.

Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation

D. Hose, H. Goldschmidt, T. Hielscher, 2013, International Journal of Hematology.

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

S. Jagannath, S. Lonial, D. Siegel, 2012 .

[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].

H. Goldschmidt, S. Delorme, T. Moehler, 2004, RöFo. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (Print).

Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy.

H. Goldschmidt, A. Ho, S. Dietrich, 2008 .

Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology

H. Goldschmidt, B. Stieltjes, F. Laun, 2011, British journal of haematology.

Extended resection of a plasmocytoma of bone and an amyloidoma of the chest wall.

H. Dienemann, P. Schnabel, U. Hegenbart, 2013, The Annals of thoracic surgery.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

T. Rème, J. Rossi, B. Klein, 2012 .